SCOPUS 정보 검색 플랫폼

Volumn 502, Issue , 2012, Pages 123-138

Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues

(4) Lyon, Robert P a Meyer, David L a Setter, Jocelyn R a Senter, Peter D a

Author keywords

Antibody reduction; Antibody drug conjugates; Conjugation strategies; Drug loading; Maleimido drug linker; Unconjugated drug content

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CYSTEINE;

ARTICLE; DRUG CONJUGATION; DRUG DETERMINATION; DRUG MANUFACTURE; DRUG MONITORING; DRUG PURIFICATION; DRUG SCREENING; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS;

EID: 84855379223 PISSN: 00766879 EISSN: 15577988 Source Type: Book Series
DOI: 10.1016/B978-0-12-416039-2.00006-9 Document Type: Chapter

Times cited : (95)

References (21)

1
- 33745508741
- Perspective - FcRn transports albumin: Relevance to immunology and medicine
- DOI 10.1016/j.it.2006.05.004, PII S1471490606001463
- C.L. Anderson Perspective - FcRn transports albumin: Relevance to immunology and medicine Trends Immunol. 27 2006 343 348 (Pubitemid 43963476)
- (2006) Trends in Immunology , vol.27 , Issue.7 , pp. 343-348
- Anderson, C.L.¹ Chaudhury, C.² Kim, J.³ Bronson, C.L.⁴ Wani, M.A.⁵ Mohanty, S.⁶

2
- 38949192547
- Targeted cancer therapy: Conferring specificity to cytotoxic drugs
- R.V. Chari Targeted cancer therapy: Conferring specificity to cytotoxic drugs Acc. Chem. Res. 41 2008 98 107
- (2008) Acc. Chem. Res. , vol.41 , pp. 98-107
- Chari, R.V.¹

3
- 10744222473
- Development of potent monoclonal antibody auristatin conjugates for cancer therapy
- DOI 10.1038/nbt832
- S.O. Doronina Development of potent monoclonal antibody auristatin conjugates for cancer therapy Nat. Biotechnol. 21 2003 778 784 (Pubitemid 36791396)
- (2003) Nature Biotechnology , vol.21 , Issue.7 , pp. 778-784
- Doronina, S.O.¹ Toki, B.E.² Torgov, M.Y.³ Mendelsohn, B.A.⁴ Cerveny, C.G.⁵ Chace, D.F.⁶ DeBlanc, R.L.⁷ Gearing, R.P.⁸ Bovee, T.D.⁹ Siegall, C.B.¹⁰ Francisco, J.A.¹¹ Wahl, A.F.¹² Meyer, D.L.¹³ Senter, P.D.¹⁴

4
- 31544441685
- Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
- DOI 10.1021/bc0502917
- S.O. Doronina Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity Bioconjug. Chem. 17 2006 114 124 (Pubitemid 43157592)
- (2006) Bioconjugate Chemistry , vol.17 , Issue.1 , pp. 114-124
- Doronina, S.O.¹ Mendelsohn, B.A.² Bovee, T.D.³ Cerveny, C.G.⁴ Alley, S.C.⁵ Meyer, D.L.⁶ Oflazoglu, E.⁷ Toki, B.E.⁸ Sanderson, R.J.⁹ Zabinski, R.F.¹⁰ Wahl, A.F.¹¹ Senter, P.D.¹²

5
- 0037013439
- Doxorubicin immunoconjugates containing bivalent, lysosomally-Cleavable dipeptide linkages
- DOI 10.1016/S0960-894X(02)00194-4, PII S0960894X02001944
- G.M. Dubowchik Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages Bioorg. Med. Chem. Lett. 12 2002 1529 1532 (Pubitemid 34521928)
- (2002) Bioorganic and Medicinal Chemistry Letters , vol.12 , Issue.11 , pp. 1529-1532
- Dubowchik, G.M.¹ Radia, S.² Mastalerz, H.³ Walker, M.A.⁴ Firestone, R.A.⁵ Dalton King, H.⁶ Hofstead, S.J.⁷ Willner, D.⁸ Lasch, S.J.⁹ Trail, P.A.¹⁰

6
- 74949139946
- Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates
- H.K. Erickson Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjug. Chem. 21 2010 84 92
- (2010) Bioconjug. Chem. , vol.21 , pp. 84-92
- Erickson, H.K.¹

7
- 6044223544
- Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
- DOI 10.1158/1078-0432.CCR-04-0789
- K.J. Hamblett Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10 2004 7063 7070 (Pubitemid 39383058)
- (2004) Clinical Cancer Research , vol.10 , Issue.20 , pp. 7063-7070
- Hamblett, K.J.¹ Senter, P.D.² Chace, D.F.³ Sun, M.M.C.⁴ Lenox, J.⁵ Cerveny, C.G.⁶ Kissler, K.M.⁷ Bernhardt, S.X.⁸ Kopcha, A.K.⁹ Zabinski, R.F.¹⁰ Meyer, D.L.¹¹ Francisco, J.A.¹²

8
- 49449087300
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- J.R. Junutula Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26 2008 925 932
- (2008) Nat. Biotechnol. , vol.26 , pp. 925-932
- Junutula, J.R.¹

9
- 77957590621
- Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer
- J.R. Junutula Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer Clin. Cancer Res. 16 2010 4769 4778
- (2010) Clin. Cancer Res. , vol.16 , pp. 4769-4778
- Junutula, J.R.¹

10
- 78651360674
- Optimizing therapeutic antibody function: Progress with Fc domain engineering
- E. Kaneko, and R. Niwa Optimizing therapeutic antibody function: Progress with Fc domain engineering BioDrugs 25 2011 1 11
- (2011) BioDrugs , vol.25 , pp. 1-11
- Kaneko, E.¹ Niwa, R.²

11
- 0037068501
- Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains
- DOI 10.1021/jm020149g
- H.D. King Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains J. Med. Chem. 45 2002 4336 4343 (Pubitemid 35025579)
- (2002) Journal of Medicinal Chemistry , vol.45 , Issue.19 , pp. 4336-4343
- King, H.D.¹ Dubowchik, G.M.² Mastalerz, H.³ Willner, D.⁴ Hofstead, S.J.⁵ Firestone, R.A.⁶ Lasch, S.J.⁷ Trail, P.A.⁸

12
- 21244469077
- Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry
- DOI 10.1002/rcm.1987
- A.C. Lazar Analysis of the composition of immunoconjugates using size-exclusion chromatography coupled to mass spectrometry Rapid Commun. Mass Spectrom. 19 2005 1806 1814 (Pubitemid 40886704)
- (2005) Rapid Communications in Mass Spectrometry , vol.19 , Issue.13 , pp. 1806-1814
- Lazar, A.C.¹ Wang, L.² Blattler, W.A.³ Amphlett, G.⁴ Lambert, J.M.⁵ Zhang, W.⁶

13
- 56449129810
- Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate
- G.D. Lewis Phillips Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68 2008 9280 9290
- (2008) Cancer Res. , vol.68 , pp. 9280-9290
- Lewis Phillips, G.D.¹

14
- 33745684533
- Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
- DOI 10.1093/protein/gzl013
- C.F. McDonagh Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment Protein Eng. Des. Sel. 19 2006 299 307 (Pubitemid 43999640)
- (2006) Protein Engineering, Design and Selection , vol.19 , Issue.7 , pp. 299-307
- McDonagh, C.F.¹ Turcott, E.² Westendorf, L.³ Webster, J.B.⁴ Alley, S.C.⁵ Kim, K.⁶ Andreyka, J.⁷ Stone, I.⁸ Hamblett, K.J.⁹ Francisco, J.A.¹⁰ Carter, P.¹¹

15
- 54049093284
- Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
- C.F. McDonagh Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index Mol. Cancer Ther. 7 2008 2913 2923
- (2008) Mol. Cancer Ther. , vol.7 , pp. 2913-2923
- McDonagh, C.F.¹

16
- 34247876138
- Development trends for monoclonal antibody cancer therapeutics
- DOI 10.1038/nrd2241, PII NRD2241
- J.M. Reichert, and V.E. Valge-Archer Development trends for monoclonal antibody cancer therapeutics Nat. Rev. Drug Discov. 6 2007 349 356 (Pubitemid 46696550)
- (2007) Nature Reviews Drug Discovery , vol.6 , Issue.5 , pp. 349-356
- Reichert, J.M.¹ Valge-Archer, V.E.²

17
- 67649886201
- Potent antibody drug conjugates for cancer therapy
- P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 3 2009 235 244
- (2009) Curr. Opin. Chem. Biol. , vol.13 , Issue.3 , pp. 235-244
- Senter, P.D.¹

18
- 64949125849
- Antibody-cytotoxic agent conjugates: Preparation and characterization
- (xiv)
- R. Singh, and H.K. Erickson Antibody-cytotoxic agent conjugates: Preparation and characterization Methods Mol. Biol. 525 2009 445 467 (xiv)
- (2009) Methods Mol. Biol. , vol.525 , pp. 445-467
- Singh, R.¹ Erickson, H.K.²

19
- 25444507922
- Reduction-alkylation strategies for the modification of specific monoclonal antibody bisulfides
- DOI 10.1021/bc050201y
- M.M. Sun Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides Bioconjug. Chem. 16 2005 1282 1290 (Pubitemid 41368132)
- (2005) Bioconjugate Chemistry , vol.16 , Issue.5 , pp. 1282-1290
- Sun, M.M.C.¹ Beam, K.S.² Cerveny, C.G.³ Hamblett, K.J.⁴ Blackmore, R.S.⁵ Torgov, M.Y.⁶ Handley, F.G.M.⁷ Ihle, N.C.⁸ Senter, P.D.⁹ Alley, S.C.¹⁰

20
- 0027218284
- Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
- P.A. Trail Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science 261 1993 212 215 (Pubitemid 23265398)
- (1993) Science , vol.261 , Issue.5118 , pp. 212-215
- Trail, P.A.¹ Willner, D.² Lasch, S.J.³ Henderson, A.J.⁴ Hofstead, S.⁵ Casazza, A.M.⁶ Firestone, R.A.⁷ Hellstrom, I.⁸ Hellstrom, K.E.⁹

21
- 78049515807
- Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
- A. Younes Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N. Engl. J. Med. 363 2010 1812 1821
- (2010) N. Engl. J. Med. , vol.363 , pp. 1812-1821
- Younes, A.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.